Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +45.04%
#3 龙虾 (Lobster) 龙虾 (Lobster) +23.45%
#4 DigiByte DigiByte +22.53%
#5 Pons Pons +21.97%
#6 OriginTrail OriginTrail +19.97%
#7 Non-Playable Coin Non-Playable Coin +18.21%
#8 ApeX ApeX +17.96%
#9 Zora Zora +17.33%
#10 Morpho Morpho +16.16%
Coin of the day
Smilek to the Bank Smilek to the Bank
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Cyteir Therapeutics, Inc. Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYT
Kedudukan dalam Saham #21570
Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Cyteir Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to innovating and bringing to market cutting-edge precision oncology medicines. Its flagship compound, CYT-0851, is an novel, orally administered small molecule drug candidate, designed for once-daily dosing. This therapy is currently undergoing Phase I/II clinical evaluations, both as a standalone treatment and in combination with other drugs, targeting a broad range of solid tumors and hematologic malignancies. Furthermore, the company is advancing CYT-1853, another promising candidate in preclinical development for similar oncological indications. Cyteir Therapeutics was established in 2012 and is headquartered in Lexington, Massachusetts.
Harga Saham
$3.01
Disegerakkan terakhir: 2024-04-12
Modal Pasaran
$104.64M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Cyteir Therapeutics, Inc. (CYT)

Kategori

Healthcare
Pendapatan untuk Cyteir Therapeutics, Inc. (CYT)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Cyteir Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Cyteir Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH